Trial Evidence — Buprenorphine and Treatment Retention

What is it?

This node represents the randomized-controlled-trial and systematic-review evidence — anchored by a Cochrane review — testing whether buprenorphine maintenance keeps people in treatment and reduces illicit opioid use compared with placebo or no medication.

Why does it matter?

Retention in treatment is closely tied to survival: people who stay on effective medication have far lower overdose risk, so evidence on retention is central to the case for MOUD.

How does it work?

In these trials participants are randomly assigned to buprenorphine or a comparator and followed to measure how long they remain in treatment and how often drug tests are negative for opioids; Cochrane pools many such trials to estimate an overall effect.

Who benefits?

Clinicians, policymakers, and payers benefit from high-quality causal evidence when deciding whether to fund and deliver buprenorphine treatment.

Who may be disadvantaged?

Trial populations and settings may not mirror every rural community, so effect sizes can differ where support services or dosing access are weaker than in a study.

What evidence exists?

The Cochrane review finds buprenorphine at adequate doses retains people in treatment better than placebo and suppresses opioid use, and NIDA summarizes convergent evidence that MOUD reduces mortality.

What tradeoffs exist?

Randomized trials give strong internal evidence but are shorter and more controlled than real-world care; sustained retention outside a trial depends on ongoing prescribing capacity and support.

Common misconceptions

The finding is not that any dose works equally — adequate dosing matters, and under-dosing is a common real-world reason people disengage despite the medication’s proven efficacy.

What you can do next

Connect this evidence to medication-assisted treatment as the intervention, and the hub-and-spoke case study for how retention is supported at scale.